Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 10/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5735099 | 0.89 | RXFP1 (0.45) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL6773600 | 0.87 | ALDH1A1 (0.55) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL5733437 | 0.87 | NHERF1 (0.49) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL6779126 | 0.86 | RXFP1 (0.48) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL6767875 | 0.86 | ALDH1A1 (0.53) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL6771471 | 0.84 | EHMT2 (0.49) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL5735016 | 0.84 | BUB1 (0.43) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL6891078 | 0.84 | LMNA (0.55) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL6773177 | 0.84 | MAPT (0.52) | RXFP1TP53THRBNTRK3NTRK2 | |
| SCHEMBL5735789 | 0.81 | NHERF1 (0.46) | NHERF1ROCK2ROCK1ALDH1A1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | claimed |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN | 2001-10-11 | — | — | US | claimed |
| EP-1019372-A1 | NOVEL FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1997026243-A1 | NOVEL FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-07-24 | — | — | WO | claimed |
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1019372-B1 | FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
| US-6515140-B2 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators; drug abruse | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN | 2001-10-11 | — | — | US | disclosed |
| US-6211365-B1 | BRAIN DISORDERS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-6080873-A | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2000-06-27 | — | — | US | disclosed |
| US-5804686-A | GAMMA-AMINOBUTYRIC ACID; AGONISTS, ANTAGONISTS, OR INVERSE AGONISTS | NEUROGEN CORPORATION (US) | 1998-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | GABRB2, GABRB1, GABRB3 | RXFP1 792/4885TP53 4107/4885THRB 426/4885 |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | RXFP1 117/4885TP53 4841/4885THRB 221/4885 |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | RXFP1 122/4885TP53 4832/4885THRB 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.